Skip to content
lifestyle.harcourthealth.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nasus Pharma, Ltd.
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
September 14, 2026
Nasus Pharma to Present at H.C. Wainwright Global Investment Conference
September 8, 2026
Nasus Pharma Announces Transition of Chief Financial Officer
August 19, 2026
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
August 17, 2026
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O’Grady as Chief Executive Officer to Lead Strategic Growth
July 28, 2026
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
June 22, 2026
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
June 9, 2026
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
June 1, 2026
Nasus Pharma to Participate in Upcoming Investor Conferences
May 1, 2026
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
March 25, 2026
1
2
Next Page
→